Assessment of Single‐Cycle M‐Protein Mutated Vesicular Stomatitis Virus as a Safe and Immunogenic Mucosal Vaccine Platform for SARS‐CoV‐2 Immunogen Delivery
Abstract The goal of the next‐generation COVID‐19 vaccine is to provide rapid respiratory tract protection with a single dose. Circulating antibodies do not protect the olfactory mucosa from viral infection, necessitating localized mucosal immunization. Live attenuated vesicular stomatitis virus (VS...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202404197 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846116849530437632 |
|---|---|
| author | En Zhang Yong Ke Weihong Ran Yu Zhang Ruihang Li Xinkui Fang Lei Wang Baohong Zhang Tao Sun |
| author_facet | En Zhang Yong Ke Weihong Ran Yu Zhang Ruihang Li Xinkui Fang Lei Wang Baohong Zhang Tao Sun |
| author_sort | En Zhang |
| collection | DOAJ |
| description | Abstract The goal of the next‐generation COVID‐19 vaccine is to provide rapid respiratory tract protection with a single dose. Circulating antibodies do not protect the olfactory mucosa from viral infection, necessitating localized mucosal immunization. Live attenuated vesicular stomatitis virus (VSVMT)‐based COVID‐19 vaccines effectively stimulate mucosal immunity in animals, though safety concerns remain, particularly in immunocompromised populations. A viral vector capable of single‐cycle replication may face less stringent regulatory requirements. A replication‐defective VSVMT is developed with its G protein replaced by a SARS‐CoV‐2 spike protein (S) mutant, where residues K986 and V987 are substituted by prolines (S2P). This studies show that single‐cycle VSVMT encoding Omicron subvariant S2P (VSVMT‐S2P) is safe in both healthy and immunocompromised animals treated with cyclophosphamide (CP). Significant antibody and T‐cell responses against the spike protein are observed in VSVMT‐S2P vaccinated healthy animals. Intramuscular VSVMT‐S2P administration induces neutralizing antibody responses comparable to those from replication‐competent VSVMT‐S. In immunocompromised animals, lower and delayed immune responses are observed. Thus, single‐cycle M‐protein mutated VSV offers a safe and effective platform for SARS‐CoV‐2 immunogen delivery. Remarkably, replication‐competent VSVMT‐S caused no pathogenicity and elicited potent mucosal immunity via intranasal administration, highlighting its potential as a mucosal COVID‐19 vaccine. |
| format | Article |
| id | doaj-art-db512b1e1d3e4fbe86388a46570b99d5 |
| institution | Kabale University |
| issn | 2198-3844 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Science |
| spelling | doaj-art-db512b1e1d3e4fbe86388a46570b99d52024-12-18T14:18:10ZengWileyAdvanced Science2198-38442024-12-011147n/an/a10.1002/advs.202404197Assessment of Single‐Cycle M‐Protein Mutated Vesicular Stomatitis Virus as a Safe and Immunogenic Mucosal Vaccine Platform for SARS‐CoV‐2 Immunogen DeliveryEn Zhang0Yong Ke1Weihong Ran2Yu Zhang3Ruihang Li4Xinkui Fang5Lei Wang6Baohong Zhang7Tao Sun8School of Agriculture and Biology Shanghai Jiao Tong University Shanghai 200240 ChinaEngineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy Shanghai Jiao Tong University Dongchuan Road, Minhang District Shanghai 200240 ChinaSchool of Agriculture and Biology Shanghai Jiao Tong University Shanghai 200240 ChinaSchool of Agriculture and Biology Shanghai Jiao Tong University Shanghai 200240 ChinaSchool of Agriculture and Biology Shanghai Jiao Tong University Shanghai 200240 ChinaSchool of Agriculture and Biology Shanghai Jiao Tong University Shanghai 200240 ChinaEngineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy Shanghai Jiao Tong University Dongchuan Road, Minhang District Shanghai 200240 ChinaEngineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy Shanghai Jiao Tong University Dongchuan Road, Minhang District Shanghai 200240 ChinaSchool of Agriculture and Biology Shanghai Jiao Tong University Shanghai 200240 ChinaAbstract The goal of the next‐generation COVID‐19 vaccine is to provide rapid respiratory tract protection with a single dose. Circulating antibodies do not protect the olfactory mucosa from viral infection, necessitating localized mucosal immunization. Live attenuated vesicular stomatitis virus (VSVMT)‐based COVID‐19 vaccines effectively stimulate mucosal immunity in animals, though safety concerns remain, particularly in immunocompromised populations. A viral vector capable of single‐cycle replication may face less stringent regulatory requirements. A replication‐defective VSVMT is developed with its G protein replaced by a SARS‐CoV‐2 spike protein (S) mutant, where residues K986 and V987 are substituted by prolines (S2P). This studies show that single‐cycle VSVMT encoding Omicron subvariant S2P (VSVMT‐S2P) is safe in both healthy and immunocompromised animals treated with cyclophosphamide (CP). Significant antibody and T‐cell responses against the spike protein are observed in VSVMT‐S2P vaccinated healthy animals. Intramuscular VSVMT‐S2P administration induces neutralizing antibody responses comparable to those from replication‐competent VSVMT‐S. In immunocompromised animals, lower and delayed immune responses are observed. Thus, single‐cycle M‐protein mutated VSV offers a safe and effective platform for SARS‐CoV‐2 immunogen delivery. Remarkably, replication‐competent VSVMT‐S caused no pathogenicity and elicited potent mucosal immunity via intranasal administration, highlighting its potential as a mucosal COVID‐19 vaccine.https://doi.org/10.1002/advs.202404197COVID‐19mucosal immunityreplication defectiveSpike proteinvesicular stomatitis virus |
| spellingShingle | En Zhang Yong Ke Weihong Ran Yu Zhang Ruihang Li Xinkui Fang Lei Wang Baohong Zhang Tao Sun Assessment of Single‐Cycle M‐Protein Mutated Vesicular Stomatitis Virus as a Safe and Immunogenic Mucosal Vaccine Platform for SARS‐CoV‐2 Immunogen Delivery Advanced Science COVID‐19 mucosal immunity replication defective Spike protein vesicular stomatitis virus |
| title | Assessment of Single‐Cycle M‐Protein Mutated Vesicular Stomatitis Virus as a Safe and Immunogenic Mucosal Vaccine Platform for SARS‐CoV‐2 Immunogen Delivery |
| title_full | Assessment of Single‐Cycle M‐Protein Mutated Vesicular Stomatitis Virus as a Safe and Immunogenic Mucosal Vaccine Platform for SARS‐CoV‐2 Immunogen Delivery |
| title_fullStr | Assessment of Single‐Cycle M‐Protein Mutated Vesicular Stomatitis Virus as a Safe and Immunogenic Mucosal Vaccine Platform for SARS‐CoV‐2 Immunogen Delivery |
| title_full_unstemmed | Assessment of Single‐Cycle M‐Protein Mutated Vesicular Stomatitis Virus as a Safe and Immunogenic Mucosal Vaccine Platform for SARS‐CoV‐2 Immunogen Delivery |
| title_short | Assessment of Single‐Cycle M‐Protein Mutated Vesicular Stomatitis Virus as a Safe and Immunogenic Mucosal Vaccine Platform for SARS‐CoV‐2 Immunogen Delivery |
| title_sort | assessment of single cycle m protein mutated vesicular stomatitis virus as a safe and immunogenic mucosal vaccine platform for sars cov 2 immunogen delivery |
| topic | COVID‐19 mucosal immunity replication defective Spike protein vesicular stomatitis virus |
| url | https://doi.org/10.1002/advs.202404197 |
| work_keys_str_mv | AT enzhang assessmentofsinglecyclemproteinmutatedvesicularstomatitisvirusasasafeandimmunogenicmucosalvaccineplatformforsarscov2immunogendelivery AT yongke assessmentofsinglecyclemproteinmutatedvesicularstomatitisvirusasasafeandimmunogenicmucosalvaccineplatformforsarscov2immunogendelivery AT weihongran assessmentofsinglecyclemproteinmutatedvesicularstomatitisvirusasasafeandimmunogenicmucosalvaccineplatformforsarscov2immunogendelivery AT yuzhang assessmentofsinglecyclemproteinmutatedvesicularstomatitisvirusasasafeandimmunogenicmucosalvaccineplatformforsarscov2immunogendelivery AT ruihangli assessmentofsinglecyclemproteinmutatedvesicularstomatitisvirusasasafeandimmunogenicmucosalvaccineplatformforsarscov2immunogendelivery AT xinkuifang assessmentofsinglecyclemproteinmutatedvesicularstomatitisvirusasasafeandimmunogenicmucosalvaccineplatformforsarscov2immunogendelivery AT leiwang assessmentofsinglecyclemproteinmutatedvesicularstomatitisvirusasasafeandimmunogenicmucosalvaccineplatformforsarscov2immunogendelivery AT baohongzhang assessmentofsinglecyclemproteinmutatedvesicularstomatitisvirusasasafeandimmunogenicmucosalvaccineplatformforsarscov2immunogendelivery AT taosun assessmentofsinglecyclemproteinmutatedvesicularstomatitisvirusasasafeandimmunogenicmucosalvaccineplatformforsarscov2immunogendelivery |